The departure of leading AI researchers from Google to found Discovery Loop raises important questions about the future ...

A small molecule inhibitor developed at Virginia Commonwealth University has demonstrated the ability to eliminate cancer ...

Dr Jonathan Cohen-Gold is Co-founder and CEO of Houdini Bio, a University of Cambridge spinout developing technology to improve the safety, durability and efficacy of cell and gene therapies. He ...

Voyager Therapeutics has presented six-month GLP toxicology data for VY1706, its investigational tau-targeting gene therapy, ...

Oblenio Bio has dosed the first patients in a Phase 1a trial of LBL-051, a tri-specific T cell engager designed to ...

What if one of gene therapy's biggest obstacles isn't delivery, but the body's own cells? Discover why DNA silencing is ...

Paul Michaels is a life sciences executive with more than two decades of experience building strategic partnerships and ...

Most inherited retinal diseases still have no approved therapy despite advances in gene therapy. This article explores why researchers are targeting shared disease mechanisms alongside individual ...

A new gene therapy platform exploiting the brain's glymphatic transport system and engineered AAV5 vectors could offer a ...

A three-drug combination targeting shared metabolic vulnerabilities in cancer and senescent cells has improved physical ...